Natalie Marrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalie Marrero has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Seamus P. Whelton
Johns Hopkins School of Medicine
6 shared publications - Wendy S. Post
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
5 shared publications - Alexander C. Razavi
Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA (A.C.R.).
4 shared publications - George Thanassoulis
McGill University
4 shared publications - Jerome I. Rotter
The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA
4 shared publications - Matthew Jay Budoff
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA
4 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in American Journal of Preventive Cardiology
Applying the 2026 dyslipidemia guideline to women’s cardiovascular prevention: a life-course commentary
- 26 October 2026
- Published by Elsevier in American Journal of Preventive Cardiology
Open AccessApplying the 2026 dyslipidemia guideline to women’s cardiovascular prevention: a life-course commentary
- Open Access
- 5 August 2026
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
Beyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction
Recent data suggest that sodium–glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium–glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.
- 5 August 2026
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
Open AccessBeyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction
Recent data suggest that sodium–glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium–glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e040064
Association of Polygenic Risk Scores With Aortic Valve Calcium: The Multi‐Ethnic Study of Atherosclerosis
Background: Aortic valve calcification (AVC) is the primary process leading to aortic stenosis. We examined whether polygenic risk scores (PRS) are associated with AVC beyond traditional atherosclerotic cardiovascular disease risk factors. Methods: We included 6812 participants in MESA (Multi‐Ethnic Study of Atherosclerosis) with computed tomography‐measured AVC at Visit 1. Using previously published PRS we calculated weighted PRS, standardized within each ancestry group. The cross‐sectional association per 1 SD higher PRS with AVC >0 was examined using multivariable logistic regression modeling with Bonferroni correction. The mean age was 62 years old, 53% were female, and 913 (13.4%) had AVC >0 at baseline. Results: The PRS for coronary artery disease (hazard ratio [HR], 1.16 [95% CI, 1.07–1.26]), systolic blood pressure (HR, 1.1 [95% CI, 1.020–1.2]), low‐density lipoprotein cholesterol (HR, 1.16 [95% CI, 1.06–1.25]), and lipoprotein(a) (HR, 1.11 [95% CI, 1.02–1.20]) were significantly associated with AVC, whereas the other PRS including coronary artery calcium (HR, 1.02 [95% CI, 0.94–1.10]) and C‐reactive protein (HR, 0.97 [95% CI, 0.89–1.05]) were not. In sex‐stratified analyses, the PRS for coronary artery disease, low‐density lipoprotein cholesterol, and lipoprotein(a) were significantly associated with AVC >0 for both sexes ( P 0 strongly suggests significant differences exist in the calcification pathways for AVC and coronary artery calcium.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e040064
Open AccessAssociation of Polygenic Risk Scores With Aortic Valve Calcium: The Multi‐Ethnic Study of Atherosclerosis
Background: Aortic valve calcification (AVC) is the primary process leading to aortic stenosis. We examined whether polygenic risk scores (PRS) are associated with AVC beyond traditional atherosclerotic cardiovascular disease risk factors. Methods: We included 6812 participants in MESA (Multi‐Ethnic Study of Atherosclerosis) with computed tomography‐measured AVC at Visit 1. Using previously published PRS we calculated weighted PRS, standardized within each ancestry group. The cross‐sectional association per 1 SD higher PRS with AVC >0 was examined using multivariable logistic regression modeling with Bonferroni correction. The mean age was 62 years old, 53% were female, and 913 (13.4%) had AVC >0 at baseline. Results: The PRS for coronary artery disease (hazard ratio [HR], 1.16 [95% CI, 1.07–1.26]), systolic blood pressure (HR, 1.1 [95% CI, 1.020–1.2]), low‐density lipoprotein cholesterol (HR, 1.16 [95% CI, 1.06–1.25]), and lipoprotein(a) (HR, 1.11 [95% CI, 1.02–1.20]) were significantly associated with AVC, whereas the other PRS including coronary artery calcium (HR, 1.02 [95% CI, 0.94–1.10]) and C‐reactive protein (HR, 0.97 [95% CI, 0.89–1.05]) were not. In sex‐stratified analyses, the PRS for coronary artery disease, low‐density lipoprotein cholesterol, and lipoprotein(a) were significantly associated with AVC >0 for both sexes ( P 0 strongly suggests significant differences exist in the calcification pathways for AVC and coronary artery calcium.
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (5) , e018849
Sex-Specific Prognostic Value of Aortic Valve Calcium and the Risk for Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis (MESA)
BACKGROUND: In general, women have lower aortic valve calcium (AVC) scores compared with men of similar age, and the AVC score threshold for diagnosing severe aortic stenosis (AS) is lower for women. We examined whether the association of AVC with the long-term risk of clinically significant AS differed for women compared with men. METHODS: AVC was measured using cardiac computed tomography among 6810 MESA (Multi-Ethnic Study of Atherosclerosis) participants. We examined AVC as a continuous (ln [AVC+1]) and categorical variable (0, 1–99, 100–299, ≥300 AU). Incident moderate or severe AS was adjudicated using standard clinical criteria with a median follow-up of 16 years. The association between AVC and AS was examined using multivariable-adjusted Cox proportional hazards regression. RESULTS: Women comprised 52.9% of participants, with AVC >0 present among 10.1% of women and 17.0% of men. There were 65 cases of incident AS in women and 75 in men. AVC as a continuous variable was associated with a higher risk of incident AS for women (hazard ratio, 1.91 [95% CI, 1.68–2.16]) and men (hazard ratio, 2.13 [95% CI, 1.88–2.41]). There was no interaction between AVC and sex ( P =0.31) for their association with AS. Women and men had similar adjusted hazards for incident AS across AVC categories, and for those with AVC ≥300, the hazard ratio was 134.9 (95% CI, 45.1–403.9) for women and 132.8 (95% CI, 6.2–274.9) for men. CONCLUSIONS: The association of AVC with the long-term risk of incident AS was similar for women and men, further supporting the utility of AVC as a prognostic marker for incident AS.
- 1 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (5) , e018849
Sex-Specific Prognostic Value of Aortic Valve Calcium and the Risk for Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis (MESA)
BACKGROUND: In general, women have lower aortic valve calcium (AVC) scores compared with men of similar age, and the AVC score threshold for diagnosing severe aortic stenosis (AS) is lower for women. We examined whether the association of AVC with the long-term risk of clinically significant AS differed for women compared with men. METHODS: AVC was measured using cardiac computed tomography among 6810 MESA (Multi-Ethnic Study of Atherosclerosis) participants. We examined AVC as a continuous (ln [AVC+1]) and categorical variable (0, 1–99, 100–299, ≥300 AU). Incident moderate or severe AS was adjudicated using standard clinical criteria with a median follow-up of 16 years. The association between AVC and AS was examined using multivariable-adjusted Cox proportional hazards regression. RESULTS: Women comprised 52.9% of participants, with AVC >0 present among 10.1% of women and 17.0% of men. There were 65 cases of incident AS in women and 75 in men. AVC as a continuous variable was associated with a higher risk of incident AS for women (hazard ratio, 1.91 [95% CI, 1.68–2.16]) and men (hazard ratio, 2.13 [95% CI, 1.88–2.41]). There was no interaction between AVC and sex ( P =0.31) for their association with AS. Women and men had similar adjusted hazards for incident AS across AVC categories, and for those with AVC ≥300, the hazard ratio was 134.9 (95% CI, 45.1–403.9) for women and 132.8 (95% CI, 6.2–274.9) for men. CONCLUSIONS: The association of AVC with the long-term risk of incident AS was similar for women and men, further supporting the utility of AVC as a prognostic marker for incident AS.
- 21 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (34) , 4792-4801
Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis
Background and Aims: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. Methods: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. Results: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19–.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04–.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04–.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001–.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66–1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53–4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39–1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14–1.47). Conclusions: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).
- 21 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (34) , 4792-4801
Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis
Background and Aims: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. Methods: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. Results: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19–.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04–.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04–.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001–.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66–1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53–4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39–1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14–1.47). Conclusions: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (2) , e018916
Race and Ethnic-Specific Burden of Aortic Valve Calcium and Its Association With Long-Term Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis
BACKGROUND: Racial and ethnic differences have been reported for aortic valve calcium (AVC) and long-term aortic stenosis (AS). Whether these differences are due to differing risk factor profiles or the burden of AVC is unknown. METHODS: Baseline AVC was quantified using the Agatston method among 6812 MESA (Multi-Ethnic Study of Atherosclerosis) participants. AVC scores were not reported to participants. The primary outcome of long-term moderate or severe AS was adjudicated using standard clinical criteria. We calculated multivariable Cox proportional hazards with log-transformed AVC as a continuous variable for each race and ethnicity. RESULTS: The mean age was 62 years, and 47% of participants were women. Over a median follow-up of 16.7 years, 140 participants were diagnosed with moderate (n=56) and severe AS (n=84). The prevalence of baseline AVC >0 by self-reported race and ethnicity was White (15.8%), Hispanic (13.3%), Black (12.3%), and Chinese (8.3%). The rate of long-term incident moderate-severe AS was highest for White participants (2.1/1000 person-years) and lowest for Chinese participants (0.5/1000 person-years). The association of AVC with moderate-severe AS was significant for all race and ethnicity groups: White hazard ratio, 1.82 (95% CI, 1.62–2.03); Hispanic hazard ratio, 2.18 (95% CI, 1.82–2.62); Black hazard ratio, 2.28 (95% CI, 1.78–2.93); and Chinese hazard ratio, 3.65 (95% CI, 1.05–12.71) per 1 unit higher log transformed AVC. There was no interaction by race and ethnicity ( P =0.26) when modeling Black versus non-Black participants. CONCLUSIONS: The racial and ethnic groups with a higher baseline prevalence of AVC had a higher long-term incidence of moderate-severe AS, but a similar relative association between AVC and moderate-severe AS regardless of baseline atherosclerotic cardiovascular disease risk. Our findings suggest that differences in AS by race and ethnicity may likely be explained by the burden of AVC.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (2) , e018916
Race and Ethnic-Specific Burden of Aortic Valve Calcium and Its Association With Long-Term Aortic Stenosis: Multi-Ethnic Study of Atherosclerosis
BACKGROUND: Racial and ethnic differences have been reported for aortic valve calcium (AVC) and long-term aortic stenosis (AS). Whether these differences are due to differing risk factor profiles or the burden of AVC is unknown. METHODS: Baseline AVC was quantified using the Agatston method among 6812 MESA (Multi-Ethnic Study of Atherosclerosis) participants. AVC scores were not reported to participants. The primary outcome of long-term moderate or severe AS was adjudicated using standard clinical criteria. We calculated multivariable Cox proportional hazards with log-transformed AVC as a continuous variable for each race and ethnicity. RESULTS: The mean age was 62 years, and 47% of participants were women. Over a median follow-up of 16.7 years, 140 participants were diagnosed with moderate (n=56) and severe AS (n=84). The prevalence of baseline AVC >0 by self-reported race and ethnicity was White (15.8%), Hispanic (13.3%), Black (12.3%), and Chinese (8.3%). The rate of long-term incident moderate-severe AS was highest for White participants (2.1/1000 person-years) and lowest for Chinese participants (0.5/1000 person-years). The association of AVC with moderate-severe AS was significant for all race and ethnicity groups: White hazard ratio, 1.82 (95% CI, 1.62–2.03); Hispanic hazard ratio, 2.18 (95% CI, 1.82–2.62); Black hazard ratio, 2.28 (95% CI, 1.78–2.93); and Chinese hazard ratio, 3.65 (95% CI, 1.05–12.71) per 1 unit higher log transformed AVC. There was no interaction by race and ethnicity ( P =0.26) when modeling Black versus non-Black participants. CONCLUSIONS: The racial and ethnic groups with a higher baseline prevalence of AVC had a higher long-term incidence of moderate-severe AS, but a similar relative association between AVC and moderate-severe AS regardless of baseline atherosclerotic cardiovascular disease risk. Our findings suggest that differences in AS by race and ethnicity may likely be explained by the burden of AVC.
- 23 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (1) , 1-9
Impact of age on aortic valve calcium progression and risk for aortic stenosis: multi-ethnic study of atherosclerosis
Aims: Aortic valve calcium (AVC) is strongly associated with the risk for severe aortic stenosis (AS). The prevalence of AVC increases with age, but the impact of age on the progression of AVC and its association with moderate-severe AS is unknown. Methods and results: Our study included 6810 participants (52.9% women) without overt cardiovascular disease between ages 45 and 84 from the Multi-Ethnic Study of Atherosclerosis. AVC was measured using non-contrast cardiac CT at Visit 1. Progression was calculated as the change in AVC divided by years between CT scans (2–10 years). Incident moderate-severe AS was adjudicated using medical chart review and echocardiogram data from Visit 6 (median follow-up of 16 years). The association between AVC and moderate-severe AS was assessed using multivariable adjusted Cox proportional hazards ratios. There were 5899 participants with AVC = 0 and 911 with AVC >0. There were 3834 participants age <65 years and 2979 age ≥65 years. The median AVC was 34.1 AU (IQR 13–1113) for participants <65 vs. 69.0 AU (IQR 23–2453) for participants ≥65. Participants 0 was associated with a similar significantly higher risk of incident moderate-severe AS for both younger (HR 13.37; 95% CI 5.67–31.52) and older participants (HR 10.59, 95% CI 6.77–16.56). Conclusion: AVC progression was significantly associated with baseline AVC burden and was similar for younger vs. older persons after accounting for baseline AVC. The presence of AVC was significantly associated with a higher long-term risk for moderate-severe AS among both younger and older participants.
- 23 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (1) , 1-9
Impact of age on aortic valve calcium progression and risk for aortic stenosis: multi-ethnic study of atherosclerosis
Aims: Aortic valve calcium (AVC) is strongly associated with the risk for severe aortic stenosis (AS). The prevalence of AVC increases with age, but the impact of age on the progression of AVC and its association with moderate-severe AS is unknown. Methods and results: Our study included 6810 participants (52.9% women) without overt cardiovascular disease between ages 45 and 84 from the Multi-Ethnic Study of Atherosclerosis. AVC was measured using non-contrast cardiac CT at Visit 1. Progression was calculated as the change in AVC divided by years between CT scans (2–10 years). Incident moderate-severe AS was adjudicated using medical chart review and echocardiogram data from Visit 6 (median follow-up of 16 years). The association between AVC and moderate-severe AS was assessed using multivariable adjusted Cox proportional hazards ratios. There were 5899 participants with AVC = 0 and 911 with AVC >0. There were 3834 participants age <65 years and 2979 age ≥65 years. The median AVC was 34.1 AU (IQR 13–1113) for participants <65 vs. 69.0 AU (IQR 23–2453) for participants ≥65. Participants 0 was associated with a similar significantly higher risk of incident moderate-severe AS for both younger (HR 13.37; 95% CI 5.67–31.52) and older participants (HR 10.59, 95% CI 6.77–16.56). Conclusion: AVC progression was significantly associated with baseline AVC burden and was similar for younger vs. older persons after accounting for baseline AVC. The presence of AVC was significantly associated with a higher long-term risk for moderate-severe AS among both younger and older participants.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (6) , e016372
Identifying People at High Risk for Severe Aortic Stenosis: Aortic Valve Calcium Versus Lipoprotein(a) and Low-Density Lipoprotein Cholesterol
BACKGROUND: Aortic valve calcification (AVC), Lp(a) [lipoprotein(a)], and low-density lipoprotein cholesterol (LDL-C) are associated with severe aortic stenosis (AS). We aimed to determine which of these risk factors were most strongly associated with the risk of incident severe AS. METHODS: A total of 6792 participants from the MESA study (Multi-Ethnic Study of Atherosclerosis) had computed tomography-quantified AVC, Lp(a), and LDL-C values at MESA visit 1 (2000–2002). We calculated the absolute event rate of incident adjudicated severe AS per 1000 person-years and performed multivariable adjusted Cox proportional hazards regression. RESULTS: The mean age was 62 years old, and 47% were women. Over a median 16.7-year follow-up, the rate of incident severe AS increased exponentially with higher AVC, regardless of Lp(a) or LDL-C values. Participants with AVC=0 had a very low rate of severe AS even with elevated Lp(a) ≥50 mg/dL (0 was strongly associated with severe AS when Lp(a) <50 mg/dL hazard ratio (HR) of 33.8 (95% CI, 16.4–70.0) or ≥50 mg/dL HR of 61.5 (95% CI, 7.7–494.2) and when LDL-C <130 mg/dL HR of 31.1 (95% CI, 14.4–67.1) or ≥130 mg/dL HR of 50.2 (95% CI, 13.2–191.9). CONCLUSIONS: AVC better identifies people at high risk for severe AS compared with Lp(a) or LDL-C, and people with AVC=0 have a very low long-term rate of severe AS regardless of Lp(a) or LDL-C level. These results suggest AVC should be the preferred prognostic risk marker to identify patients at high risk for severe AS, which may help inform participant selection for future trials testing novel strategies to prevent severe AS.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (6) , e016372
Identifying People at High Risk for Severe Aortic Stenosis: Aortic Valve Calcium Versus Lipoprotein(a) and Low-Density Lipoprotein Cholesterol
BACKGROUND: Aortic valve calcification (AVC), Lp(a) [lipoprotein(a)], and low-density lipoprotein cholesterol (LDL-C) are associated with severe aortic stenosis (AS). We aimed to determine which of these risk factors were most strongly associated with the risk of incident severe AS. METHODS: A total of 6792 participants from the MESA study (Multi-Ethnic Study of Atherosclerosis) had computed tomography-quantified AVC, Lp(a), and LDL-C values at MESA visit 1 (2000–2002). We calculated the absolute event rate of incident adjudicated severe AS per 1000 person-years and performed multivariable adjusted Cox proportional hazards regression. RESULTS: The mean age was 62 years old, and 47% were women. Over a median 16.7-year follow-up, the rate of incident severe AS increased exponentially with higher AVC, regardless of Lp(a) or LDL-C values. Participants with AVC=0 had a very low rate of severe AS even with elevated Lp(a) ≥50 mg/dL (0 was strongly associated with severe AS when Lp(a) <50 mg/dL hazard ratio (HR) of 33.8 (95% CI, 16.4–70.0) or ≥50 mg/dL HR of 61.5 (95% CI, 7.7–494.2) and when LDL-C <130 mg/dL HR of 31.1 (95% CI, 14.4–67.1) or ≥130 mg/dL HR of 50.2 (95% CI, 13.2–191.9). CONCLUSIONS: AVC better identifies people at high risk for severe AS compared with Lp(a) or LDL-C, and people with AVC=0 have a very low long-term rate of severe AS regardless of Lp(a) or LDL-C level. These results suggest AVC should be the preferred prognostic risk marker to identify patients at high risk for severe AS, which may help inform participant selection for future trials testing novel strategies to prevent severe AS.
- 27 May 2024
- Published by Elsevier in Atherosclerosis
- Vol. 397, 117596
Association of aortic valve calcium with dementia and stroke: The Multi-Ethnic Study of Atherosclerosis
- 27 May 2024
- Published by Elsevier in Atherosclerosis
- Vol. 397, 117596
Association of aortic valve calcium with dementia and stroke: The Multi-Ethnic Study of Atherosclerosis